Fresenius Medical Care AG & Co. KGaA (FMS) Expected to Announce Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of $0.47 per share for the quarter.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.25% and a net margin of 3.18%. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock traded down $0.38 during trading hours on Thursday, reaching $26.82. The company had a trading volume of 115,485 shares, compared to its average volume of 364,072. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.46 and a quick ratio of 1.08. The stock has a fifty day moving average of $28.08 and a 200-day moving average of $25.57. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $17.93 and a 12-month high of $30.46.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Friday, June 6th. Investors of record on Friday, May 23rd were given a $0.7871 dividend. This represents a yield of 1.9%. This is a positive change from Fresenius Medical Care AG & Co. KGaA's previous annual dividend of $0.44. The ex-dividend date of this dividend was Friday, May 23rd. Fresenius Medical Care AG & Co. KGaA's dividend payout ratio is presently 50.89%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Truist Financial increased their price objective on Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a "hold" rating in a research report on Monday, May 12th. Morgan Stanley restated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Thursday, May 15th. Finally, Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong-buy" rating in a research note on Saturday, July 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $27.80.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

An institutional investor recently raised its position in Fresenius Medical Care AG & Co. KGaA stock. AQR Capital Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 14.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,297 shares of the company's stock after acquiring an additional 1,777 shares during the period. AQR Capital Management LLC's holdings in Fresenius Medical Care AG & Co. KGaA were worth $356,000 at the end of the most recent reporting period. Institutional investors own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.